Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169780 | 0.80 | — | — | |
| SCHEMBL28925316 | 0.78 | KDM4E (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22321405 | 0.78 | KDM4E (0.31) | — | |
| SCHEMBL8958844 | 0.77 | CYP3A4 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2003555 | 0.74 | CYP3A4 (0.33) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL1031810 | 0.74 | GRM5 (0.35) | HTTL3MBTL1GAA | |
| SCHEMBL16178834 | 0.72 | — | — | |
| SCHEMBL1029938 | 0.71 | KDM4E (0.40) | LMNAMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL29472099 | 0.69 | CYP3A4 (0.39) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5139880 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-3595633-B1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | DFB SORIA, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | DFB SORIA, LLC | 2023-02-09 | — | — | US | disclosed |
| US-11331278-B2 | Delivery of drug nanoparticles and methods of use thereof | DFB SORIA, LLC (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220117882-A1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | DFB SORIA, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220047513-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| EP-1680223-A4 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | FQUBED INC (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| US-20070183936-A1 | Apparatus and methods for evaluating the barrier properties of a membrane | NUVO RESEARCH US, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2006091297-A2 | MOLECULES TO ENHANCE PERCUTANEOUS DELIVERY AND METHODS FOR DISCOVERY THEREFOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1680223-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | Fqubed, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005012549-A2 | APPARATUS AND METHODS FOR EVALUATING THE BARRIER PROPERTIES OF A MEMBRANE | FQUBED, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2002016941-A2 | A COMBINATORIAL METHOD FOR RAPID SCREENING OF DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | HDAC3 644/4885HDAC4 1156/4885HDAC1 494/4885 |
| US-11633349-B2 | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes | KRT18, TUBB3, TUBA3E | HDAC3 3978/4885HDAC4 3299/4885HDAC1 2649/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | HDAC3 644/4885HDAC4 1156/4885HDAC1 494/4885 |
| US-20230038716-A1 | TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND CERVICAL CANCER USING NANOPARTICLES OF TAXANES | NCL, HUNK, LMNB1 | HDAC3 2459/4885HDAC4 1181/4885HDAC1 1530/4885 |
| US-20220117882-A1 | TOPICAL THERAPY FOR THE TREATMENT OF SKIN MALIGNANCIES USING NANOPARTICLES OF TAXANES | KRT18, TUBB3, TUBA3E | HDAC3 3978/4885HDAC4 3299/4885HDAC1 2649/4885 |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | NOTUM, TRPV1, TRPV4 | HDAC3 4109/4885HDAC4 2017/4885HDAC1 3162/4885 |
| US-11331278-B2 | Delivery of drug nanoparticles and methods of use thereof | VCL, BRCA1, KRT18 | HDAC3 2970/4885HDAC4 3347/4885HDAC1 1816/4885 |
| US-11583499-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | HDAC3 2768/4885HDAC4 3043/4885HDAC1 2529/4885 |
| US-20220047513-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | TP53, IPO5, NUP205 | HDAC3 2768/4885HDAC4 3043/4885HDAC1 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.